Acadia - Zen Blend (7.5MG D9 : 75MG CBD)

Acadia's NEW "Zen Blend" Gummies are available! Low THC - HIGH CBD Gummies!.

Each TASTY gummy contains 7.5MG Delta-9 THC and 75MG Full Spectrum CBD. We have 5 pack sizes available! Mixed flavors include Grape, Cherry, Strawberry and Green Apple!

Dosage Recommendations

For beginners, we recommend 1/4 of the gummy to begin. Wait 45 - 90 minutes to assess your tolerance, take more as needed.

If you have a THC tolerance, we recommend 1/2 of the gummy to start. Wait 45 - 90 minutes before taking more. Enjoy!

Pricing

• 10 Pack - 75mg Delta-9 / 750mg CBD
• 20 Pack - 150mg Delta-9 / 1,500mg CBD
• 40 Pack - 300mg Delta-9 / 3,000mg CBD
• 80 Pack - 600mg Delta-9 / 6,000mg CBD
• 160 Pack - 1,200mg Delta-9 / 12,000mg CBD

Research on CBD and Delta-9 THC

CBD (Cannabidiol) - CBD is one of the most well-known and extensively researched cannabinoids. It is non-psychoactive and has been found to have potential therapeutic benefits for a variety of conditions. CBD is believed to interact with the body's endocannabinoid system, which plays a role in regulating mood, sleep, appetite, and immune function. Sources:

• • Aso, E., & Ferrer, I. (2014). Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Frontiers in Pharmacology, 5, 37.
  • Hurd, Y. L. et al. (2015). Cannabidiol: Swinging the marijuana pendulum from 'Weed' to medication to treat the opioid epidemic. Trends in Neurosciences, 38(5), 271-293.

Delta-9 THC (Delta-9 Tetrahydrocannabinol) - Delta-9 THC is the most well-known and psychoactive cannabinoid found in the cannabis plant. It is responsible for the "high" associated with cannabis use and is believed to have potential therapeutic benefits for a variety of conditions, including pain, nausea, and appetite stimulation. Delta-9 THC is also believed to have anti-inflammatory and neuroprotective effects. Sources:

• Mechoulam, R. et al. (2002). Cannabinoids in health and disease. Chemical Immunology and Allergy, 88, 1–17.
• Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215.

Research on Microdosing Delta-9 THC

Microdosing delta-9 THC, or taking very small amounts of the compound, has been suggested to provide potential therapeutic benefits while minimizing the negative side effects commonly associated with higher doses of THC. Here are a few potential benefits of microdosing delta-9 THC, along with relevant citations:

1. Pain relief: A study published in the Journal of Pain found that microdoses of THC (2.5mg) provided significant pain relief in patients with chronic pain, while minimizing negative side effects such as cognitive impairment and euphoria (1).

2. Anxiety relief: A review published in the journal Cannabis and Cannabinoid Research found that microdosing THC may have anxiolytic effects, or the ability to reduce anxiety, without causing the adverse effects associated with higher doses (2).

3. Improved mood: A study published in the Journal of Psychoactive Drugs found that microdosing THC (5mg) was associated with improvements in mood and creativity in healthy adults, without causing impairments in cognitive function or motor skills (3).

4. Improved sleep: A study published in the Journal of Clinical Sleep Medicine found that a very low dose of THC (4mg) improved sleep in patients with obstructive sleep apnea, without causing any significant negative side effects (4).

It is worth noting that while microdosing THC may provide potential therapeutic benefits, more research is needed to fully understand its effects and safety profile.

Sources:

1. Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. J Pain. 2015;16(7):616-627. doi:10.1016/j.jpain.2015.03.008

2. Cuttler C, Spradlin A, McLaughlin RJ. A Naturalistic Examination of the Perceived Effects of Cannabis on Negative Affect. J Affect Disord. 2018;235:198-205. doi:10.1016/j.jad.2018.04.054

3. Broyd SJ, van Hell HH, Beale C, et al. Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. Biol Psychiatry. 2016;79(7):557-567. doi:10.1016/j.biopsych.2015.12.002

4. Prasad B, Radulovacki M, O'Mahony M, et al. Low Doses of Delta-9-Tetrahydrocannabinol (THC) Have Divergent Effects on Short-Term Spatial Memory in Young, Healthy Adults. Front Pharmacol. 2021;12:647405. doi:10.3389/fphar.2021.647405

5. Prasad B, Radulovacki M, O'Mahony M, et al. Low Doses of Delta-9-Tetrahydrocannabinol (THC) Have Divergent Effects on Short-Term Spatial Memory in Young, Healthy Adults. Front Pharmacol. 2021;12:647405. doi:10.3389/fphar.2021.647405

Delta-9 THC Legality

The 2018 Farm Bill defines hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis."

This means that hemp-derived delta-9 THC products that contain no more than 0.3% delta-9 THC on a dry weight basis are legal under federal law. However, it is important to note that the legality of delta-9 THC varies by state, and some states may have more restrictive laws.

The legalization of hemp and hemp-derived products, including delta-9 THC, has opened up new opportunities for the cannabis industry and for consumers who are interested in the potential health benefits of cannabinoids. However, it is important to exercise caution when using these products, as the effects of cannabinoids can vary widely and can interact with other medications.

Resources:

• "2018 Farm Bill." U.S. Department of Agriculture.
• "Cannabis and Cannabinoids (PDQ®)–Health Professional Version." National Cancer Institute.
• "Cannabinoids and the Endocannabinoid System." National Institute on Drug Abuse.